Effects of dexmedetomidine at the same concentration combined with ropivacaine on mothers and infants during epidural labor analgesia

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200061040

Enrollment

Unknown

Registered

2022-06-15

Start date

2022-06-01

Completion date

Unknown

Last updated

2023-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Labor pain

Interventions

A:0.05% ropivacaine combined with 4ug/ml dexmedetomidine

B:0.0625% ropivacaine combined with 4ug/ml dexmedetomidine

C:0.0625 ropivacaine combined with 4ug/ml dexmedetomidine

D:0.0875%ropivacaine combined with 4ug/ml dexmedetomidine

E:0.1%ropivacaine combined with 4ug/ml dexmedetomidine

Eligibility

Sex/Gender

Female

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Singleton pregnancy; 2. American Society of Anesthesiologists (ASA) physical II; 3. Aged 18-45 years; 4. Gestational aged 37 to 41 weeks; 5. Height between 150 to 170 cetimeters; 6.BM I<= 35 kg/m2.

Exclusion criteria

Exclusion criteria: 1. Paturients with contraindications to regional anesthesia; 2. Allergic to dexmedetomidine or local anesthetics; 3. Preoperative eclampsia, hypertension,diabetes comorbidities or complications.

Design outcomes

Primary

Measure	Time frame
VAS score;	—

Countries

China

Contacts

Public ContactJun Yin

2967118@qq.com+86 15988361587

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026